Phenylbutyrate inhibits growth of cervical carcinoma cells independent of HPV type and copy number

Journal of Cancer Research and Clinical Oncology

Volumn 129, Issue 2, 2003, Pages 107-113

  Finzer, P ^a   Stohr M ^a   Seibert, N ^a   Rosl F ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

HDAC inhibitors; HPV; p21; p27; Therapy

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; CYCLIN DEPENDENT KINASE INHIBITOR; PHENYLACETIC ACID; PROTEIN P21; PROTEIN P27;

ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL CYCLE; DOSE RESPONSE; DRUG CYTOTOXICITY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA; VIRUS TYPING; WART VIRUS; WESTERN BLOTTING;

EID: 0344951326     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-003-0416-z     Document Type: Article

References (43)

1. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA, Howley PM (1987) Structural and transcriptional analysis of human papillomavirus type 16 sequences in cervical carcinoma cell lines. J Virol 61:962-971
2. Bartsch D, Boye B, Baust C, zur Hausen H, Schwarz E (1992) Retinoic acid-mediated repression of human papillomavirus 18 transcription and different ligand regulation of the retinoic acid receptor beta gene in non-tumorigenic and tumorigenic HeLa hybrid cells. EMBO J 11:2283-2291
3. Brusilow SW, Danney M, Waber LJ, Batshaw M, Burton B, Levitsky L, Roth K, McKeethren C, Ward J (1984) Treatment of episodic hyperammonemia in children with inborn errors of urea synthesis. N Engl J Med 310:1630-1634
4. Burlina AB, Ogler H, Korall H, Trefz FK (2001) Long-term treatment with sodium phenylbutyrate in ornithine transcarbamylase-deficient patients. Mol Genet Metab 72:351-355
5. Calvaruso G, Carabillo M, Giuliano M, Lauricella M, dAnneo A, Vento R, Tesoriere G (2001) Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: the effect of combined treatment with the topoisomerase I-inhibitor topotecan. Int J Oncol 18:1233-1237
6. Choo KB, Pan CC, Han SH (1987) Integration of human papillomavirus type 16 into cellular DNA of cervical carcinoma: preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 161:259-261
7. Daniel P, Brazier M, Cerruti I, Pieri F, Tardivel I, Desmet G, Baillet J, Chany C (1989) Pharmacokinetic study of butyric acid administered in vivo as sodium and arginine butyrate salt. Clin Chim Acta 181:255-263
8. Dean PN, Jett JH (1974) Mathematical analysis of DNA distributaion derived from flow microfluorometry. J Cell Biol 60:523
9. DiBenedetto M, Kourbali Y, Starzec A, Vassy R, Jozefonvicz J, Perret G, Crepin M, Kraemer M (2001) Sodium phenylacetate enhances the inhibitory effect of dextran derivative on breast cancer cell growth in vitro and in nude mice. Br J Cancer 85:917-923
10. DiGiuseppe J, Weng LJ, Yu KH, Fu S, Kastan MB, Samid D, Gore SD (1999) Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: structure-function analysis. Leukemia 13:1243-1253
11. Dover GJ, Brusilow S, Charache S (1994) Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84:339-343
12. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vorgelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817-825
13. Finzer P, Kuntzen C, Soto U, zur Hausen H, Rösl F (2001) Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 20:4768-4776
14. Finzer P, Ventz R, Kuntzen C, Seibert N, Soto U, Rösl F (2002) Growth arrest of HPV-positive cells after histone deacetylase inhibition is independent of E6/E7 oncogene expression. Virology 304:265-273
15. Funk JO, Waga S, Harry JB, Espling E, Stillman B, Galloway DA (1997) Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV 16 E7 oncoprotein. Genes Dev 11:2090-2100
16. Gilbert J, Baker SD, Bowling MK, Grochow L, Figg WD, Zabelina Y, Donehower RC, Carducci MA (2001) A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 7:2292-2300
17. Gore SD, Samid D, Weng LJ (1997) Impact of the putative differentiating agents sodium phenylbutyrate and sodium phenylacetate on proliferation, differentiation, and apoptosis of primary neoplastic myeloid cells. Clin Cancer Res 3:1755-1762
18. Harrison LW, Wojciechowicz DC, Brennan MF, Paty PB (1998) Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma. Surgery 124:541-550
19. Kramer OH, Gottlicher M, Heinzel T (2001) Histone deacetylase as a therapeutic target. Trends Endocrinol Metab 12:294-300
20. Jeon S, Lambert PF (1995) Integration of human papillomavirus type 16 into the human genome leads to increased stability of E6 and E7 mRNAs: implications for cervical carcinogenesis. Proc Natl Acad Sci USA 92:1654-1658
21. Marks PA, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK (2001) Histone deacetylases and cancer: causes and therapies. Nature Rev Cancer 1:194-202
22. McGuinness MC, Wei H, Smith KD (2000) Therapeutic developments in peroxisome biogenesis disorder. Expert Opin Investig Drugs 9:1985-1992
23. Mincheva A, Gissmann L, zur Hausen H (1987) Chromosomal integration sites of human papillomavirus DNA in three cervical cancer cell lines mapped by in situ hybridization. Med Microbiol Immunol (Berl) 176:245-256
24. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD (2001) Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and up-regulate proliferation-associated and NF-κB-responsive genes in cervical keratinocytes. J Virol 75:4283-4296
25. Newmark HL, Young CW (1995) Butyrate and phenylacetate as differentiating agents: practical problems and opportunities. J Cell Biochem Suppl 22:247-253
26. Ng AY, Bales W, Veltri RW (2000) Phenylbutyrate-induced apoptosis and differential expression of bc1-2, bax, p53 and Fas in human prostate cancer cell lines. Anal Quant Cytol Histol 22:45-54
27. Ozawa T, Lu RM, Hu LJ, Lamborn KR, Prados MD, Deen DF (1999) Radiopotentiation of human brain tumor cells by sodium phenylacetate. Cancer Lett 142:139-146
28. Pill R, Kruszewski MP, Hager BW, Lantz J, Carducci MA (2001) Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis. Cancer Res 61:1477-1485
29. Pirisi L, Batova A, Jenkins GR, Hodam JR, Creek KE (1992) Increased sensitivity of human keratinocytes immortalized by human papillomavirus type 16 DNA to growth control by retinoids. Cancer Res 52:187-93
30. Pisani P, Bray F, Parkin DM (2002) Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97:72-81
31. Piscitelli SC, Thibault A, Figg WD, Tompkins A, Headlee D, Lieberman R, Samid D, Myers CE (1995) Disposition of phenylbutyrate and its metabolites, phenylacetate and phenylacetylglutamine. J Clin Pharmacol 35:368-373
32. Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, Massague J (1994) Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extra-cellular antimitogenic signals. Cell 78:59-66
33. Popescu NC, Amsbaugh SC, DiPaolo JA (1987a) Human papillomavirus type 18 DNA is integrated at a single chromosome site in cervical carcinoma cell lines SW756. J Virol 51:1682-1685
34. Popescu NC, DiPaolo JA, Amsbaugh SC (1987b) Integration sites of human papillomavirus 18 DNA sequences on HeLa cell chromosomes. Cytogenet Cell Genet 44:58-62
35. Rösl F, Westphal E-M, zur Hausen H (1989) Chromatin sturcture and transcriptional regulation of human papillomavirus type 18 DNA in HeLa cells. Mol Carcinogenesis 2:72-80
36. Schwarz E, Freese UK, Gissmann L, Mayer W, Roggenbuck B, zur Hausen H (1985) Structure and transcription of human papillomavirus type 18 and 16 sequences in cervical carcinoma cells. Nature 314:111-114
37. Smits HL, Cornelissen MTE, Jebbink MF, van den Tweel JG, Struyk APHB, Briet M, ter Schegget J (1991) Human papillomavirus type 16 transcripts expressed from viral-cellular junctions and full-length viral copies in CaSki cells and in cervical carcinoma. Virol 182:870-873
38. Stoehr M, Vogt-Schaden M, Knobloch M, Vogel R, Futterman G (1978) Evaluation of eight fluorochrome combinations for simulataneous DNA-protein flow analyses. Stain Technol 55:205-215
39. Wang QM, Feinman R, Kashanchi F, Houghton JM, Studzinski GP, Harrison LE (2000) Changes in E2F binding after phenylbutyrate-induced differentiation of Caco-2 cancer cells. Clin Cancer Res 6:2951-2958
40. Witzig TE, Timm M, Stenson M, Svingen PA, Kaufmann SH (2000) Induction of apoptosis in malignant B cells by phenylbutyrate or phenylacetate in combination with chemotherapeutic agents. Clin Cancer Res 6:681-692
41. KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene 13:2323-2330
42. zur Hausen H (2000) Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92:690-698
43. zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2:342-350